In this study, we defined the role of
peroxisome proliferator-activated receptor beta/delta (
PPARdelta) in metabolic homeostasis by using subtype selective agonists. Analysis of rat L6 myotubes treated with the
PPARdelta subtype-selective agonist,
GW501516, by the Affymetrix
oligonucleotide microarrays revealed that
PPARdelta controls
fatty acid oxidation by regulating genes involved in
fatty acid transport, beta-oxidation, and mitochondrial respiration. Similar
PPARdelta-mediated gene activation was observed in the skeletal muscle of GW501516-treated mice. Accordingly,
GW501516 treatment induced
fatty acid beta-oxidation in L6 myotubes as well as in mouse skeletal muscles. Administration of
GW501516 to mice fed a high-fat diet ameliorated diet-induced
obesity and
insulin resistance, an effect accompanied by enhanced metabolic rate and
fatty acid beta-oxidation, proliferation of mitochondria, and a marked reduction of lipid droplets in skeletal muscles. Despite a modest
body weight change relative to vehicle-treated mice,
GW501516 treatment also markedly improved diabetes as revealed by the decrease in plasma
glucose and blood
insulin levels in genetically obese ob/ob mice. These data suggest that
PPARdelta is pivotal to control the program for
fatty acid oxidation in the skeletal muscle, thereby ameliorating
obesity and
insulin resistance through its activation in obese animals.